1
|
Dogadov DI, Kyuregyan KK, Mikhailov MI. [Enteral viral hepatitis in monkeys]. Vopr Virusol 2022; 67:173-184. [PMID: 35831960 DOI: 10.36233/0507-4088-110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Accepted: 07/13/2022] [Indexed: 06/15/2023]
Abstract
Within the last decade, a large number of viruses genetically related to human hepatitis viruses have been identified in different animal species, including monkeys. Numerous viruses related to human hepatitis A virus (HAV, Picornaviridae: Hepatovirus: Hepatovirus A) were detected in various mammalian species in 2015-2018, predominantly in bats and rodents, but also in shrews, seals and marsupials. Zoonotic hepatitis E virus (HEV, Hepeviridae: Orthohepevirus: Orthohepevirus A) genotypes have been found in wild boars, deer, camels, and rabbits, as well as in non human primates. In addition, viruses that are genetically close to HEV have been described in bats, ferrets, rodents, birds, and fish. Nevertheless, monkeys remain important laboratory animals in HAV and HEV research. The study of spontaneous and experimental infection in these animals is an invaluable source of information about the biology and pathogenesis of these viruses and continues to be an indispensable tool for vaccine and drug testing. The purpose of this literature review was to summarize and analyze published data on the circulation of HAV and HEV among wild and captive primates, as well as the results of experimental studies of HAV and HEV infections in monkeys.
Collapse
Affiliation(s)
- D I Dogadov
- FSBRI «Research Institute of Medical Primatology» of the Ministry of Education and Science of Russia
| | - K K Kyuregyan
- FSBRI «Research Institute of Medical Primatology» of the Ministry of Education and Science of Russia; FSBRI «I.I. Mechnikov Research Institute of Vaccines and Sera»
| | - M I Mikhailov
- FSBRI «I.I. Mechnikov Research Institute of Vaccines and Sera»; FSBEI FPE «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of Russia
| |
Collapse
|
2
|
Gordeychuk I, Kyuregyan K, Kondrashova A, Bayurova E, Gulyaev S, Gulyaeva T, Potemkin I, Karlsen A, Isaeva O, Belyakova A, Lyashenko A, Sorokin A, Chumakov A, Morozov I, Isaguliants M, Ishmukhametov A, Mikhailov M. Immunization with recombinant ORF2 p551 protein protects common marmosets (Callithrix jacchus) against homologous and heterologous hepatitis E virus challenge. Vaccine 2022; 40:89-99. [PMID: 34836660 DOI: 10.1016/j.vaccine.2021.11.042] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 10/18/2021] [Accepted: 11/14/2021] [Indexed: 12/23/2022]
Abstract
BACKGROUND Hepatitis E virus (HEV) is a major causative agent of acute hepatitis worldwide, prompting continuous HEV vaccine efforts. Vaccine development is hampered by the lack of convenient animal models susceptible to infection with different HEV genotypes. We produced recombinant open reading frame 2 protein (pORF2; p551) of HEV genotype (GT) 3 and assessed its immunogenicity and protectivity against HEV challenge in common marmosets (Callithrix jacchus, CM). METHODS p551 with consensus sequence corresponding to amino acid residues 110-660 of HEV GT3 pORF2 was expressed in E. coli and purified by affinity chromatography. CMs were immunized intramuscularly with 20 μg of p551 VLPs with alum adjuvant (n = 4) or adjuvant alone (n = 2) at weeks 0, 3, 7 and 19. At week 27, p551-immunized and control animals were challenged with HEV GT1 or GT3 and thereafter longitudinally screened for markers of liver function, anti-HEV IgG and HEV RNA in feces and sera. RESULTS Purified p551 formed VLPs with particle size of 27.71 ± 2.42 nm. Two immunizations with p551 induced anti-HEV IgG mean titer of 1:1810. Immunized CMs challenged with homologous and heterologous HEV genotype did not develop HEV infection during the follow-up. Control CMs infected with both HEV GT1 and GT3 demonstrated signs of HEV infection with virus shedding and elevation of the levels of liver enzymes. High levels of anti-HEV IgG persisted in vaccinated CMs and control CMs that resolved HEV infection, for up to two years post challenge. CONCLUSIONS CMs are shown to be a convenient laboratory animal model susceptible to infection with HEV GT1 and GT3. Immunization with HEV GT3 ORF2/p551 triggers potent anti-HEV antibody response protecting CMs from homologous and heterologous HEV challenge. This advances p551 in VLPs as a prototype vaccine against HEV.
Collapse
Affiliation(s)
- Ilya Gordeychuk
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia; Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 127994, Russia.
| | - Karen Kyuregyan
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia; I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow 105064, Russia; Russian Medical Academy of Continuous Professional Education, Moscow 125993, Russia.
| | - Alla Kondrashova
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia; Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 127994, Russia
| | - Ekaterina Bayurova
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia.
| | - Stanislav Gulyaev
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia.
| | - Tatiana Gulyaeva
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia.
| | - Ilya Potemkin
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia; I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow 105064, Russia; Russian Medical Academy of Continuous Professional Education, Moscow 125993, Russia.
| | - Anastasia Karlsen
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia; I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow 105064, Russia; Russian Medical Academy of Continuous Professional Education, Moscow 125993, Russia; N.F. Gamaleya Federal Research Center for Epidemiology & Microbiology, Moscow 123098, Russia
| | - Olga Isaeva
- I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow 105064, Russia; Russian Medical Academy of Continuous Professional Education, Moscow 125993, Russia.
| | - Alla Belyakova
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia.
| | - Anna Lyashenko
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia.
| | - Alexey Sorokin
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia
| | - Alexey Chumakov
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia; Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 127994, Russia
| | - Igor Morozov
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia.
| | - Maria Isaguliants
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia; N.F. Gamaleya Federal Research Center for Epidemiology & Microbiology, Moscow 123098, Russia; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177 Stockholm, Sweden.
| | - Aydar Ishmukhametov
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia; Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow 127994, Russia.
| | - Mikhail Mikhailov
- I.I. Mechnikov Research Institute of Vaccines and Sera, Moscow 105064, Russia; Russian Medical Academy of Continuous Professional Education, Moscow 125993, Russia.
| |
Collapse
|
3
|
Molina CV, Heinemann MB, Kierulff C, Pissinatti A, da Silva TF, de Freitas DG, de Souza GO, Miotto BA, Cortez A, Semensato BDP, Moreno LZ, Catão-Dias JL, Bueno MG. Leptospira spp., rotavirus, norovirus, and hepatitis E virus surveillance in a wild invasive golden-headed lion tamarin (Leontopithecus chrysomelas; Kuhl, 1820) population from an urban park in Niterói, Rio de Janeiro, Brazil. Am J Primatol 2019; 81:e22961. [PMID: 30828830 DOI: 10.1002/ajp.22961] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Revised: 01/18/2019] [Accepted: 02/03/2019] [Indexed: 01/13/2023]
Abstract
The world currently faces severe biodiversity losses caused by anthropogenic activities such as deforestation, pollution, the introduction of exotic species, habitat fragmentation, and climate changes. Disease ecology in altered environments is still poorly understood. The golden-headed lion tamarin (GHLT, Leontopithecus chrysomelas) is an endangered species that became invasive in an urban park in Niterói, Rio de Janeiro, Brazil. The initially few invasive GHLT individuals became hundreds, adapted to living in proximity to humans and domestic animals. These GHLTs were captured as part of a conservation project; some animals were translocated to Bahia and some were kept in captivity. This study tested 593 GHLT for Leptospira serology; 100 and 95 GHLT for polymerase chain reaction (PCR) toLeptospira and hepatitis E virus genotype 3 (HEV-3), respectively, and 101 familiar groups for PCR to viruses (rotavirus A, norovirus GI and GII, and HEV-3). One animal had antibodies for Leptospira serovar Shermani and another for serovar Hebdomadis. One saprophyticLeptospira was found by the 16S PCR and sequencing. Viruses were not detected in samples tested. Findings suggest that the epidemiological importance of such pathogens in this GHLT population is either low or nonexistent. These data are important to understand the local disease ecology, as well as monitoring a translocation project, and to contribute data for species conservation.
Collapse
Affiliation(s)
- Camila V Molina
- Laboratório de Patologia Comparada de Animais Selvagens (LAPCOM), Departamento de Patologia (VPT), Faculdade de Medicina Veterinária e Zootecnia (FMVZ), Universidade de São Paulo (USP), São Paulo, SP, Brazil.,Instituto Pri-Matas para a Conservação da Biodiversidade, Belo Horizonte, MG, Brazil
| | - Marcos B Heinemann
- Laboratório de Zoonoses Bacterianas, Departamento de Medicina Veterinária Preventiva e Saúde Animal (VPS), Faculdade de Medicina Veterinária e Zootecnia (FMVZ), Universidade de São Paulo (USP), São Paulo, SP, Brazil
| | - Cecilia Kierulff
- Instituto Pri-Matas para a Conservação da Biodiversidade, Belo Horizonte, MG, Brazil.,Programa de Pós-graduação em Biodiversidade Tropical, Universidade Federal do Espírito Santo (UFES), São Mateus, ES, Brazil
| | - Alcides Pissinatti
- Centro de Primatologia do Rio de Janeiro (CPRJ), Instituto Estadual do Ambiente (INEA), Guapimirim, RJ, Brazil.,Centro Universitário Serra dos Órgãos, Teresópolis, RJ, Brazil
| | - Tiago F da Silva
- Instituto Pri-Matas para a Conservação da Biodiversidade, Belo Horizonte, MG, Brazil
| | - Danilo G de Freitas
- Instituto Pri-Matas para a Conservação da Biodiversidade, Belo Horizonte, MG, Brazil
| | - Gisele O de Souza
- Laboratório de Zoonoses Bacterianas, Departamento de Medicina Veterinária Preventiva e Saúde Animal (VPS), Faculdade de Medicina Veterinária e Zootecnia (FMVZ), Universidade de São Paulo (USP), São Paulo, SP, Brazil
| | - Bruno A Miotto
- Departamento de Clínica Médica (VCM), Faculdade de Medicina Veterinária e Zootecnia (FMVZ), Universidade de São Paulo (USP), São Paulo, SP, Brazil
| | - Adriana Cortez
- Curso de Medicina Veterinária, Universidade Santo Amaro (UNISA), São Paulo, SP, Brazil
| | | | - Luisa Z Moreno
- Laboratório de Sanidade Suína, Departamento de Medicina Veterinária Preventiva e Saúde Animal (VPS), Faculdade de Medicina Veterinária e Zootecnia (FMVZ), Universidade de São Paulo (USP), São Paulo, SP, Brazil
| | - José L Catão-Dias
- Laboratório de Patologia Comparada de Animais Selvagens (LAPCOM), Departamento de Patologia (VPT), Faculdade de Medicina Veterinária e Zootecnia (FMVZ), Universidade de São Paulo (USP), São Paulo, SP, Brazil
| | - Marina G Bueno
- Instituto Pri-Matas para a Conservação da Biodiversidade, Belo Horizonte, MG, Brazil.,Presidência, Plataforma Institucional Biodiversidade e Saúde Silvestre, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil
| |
Collapse
|